Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of HX575 recombinant human erythropoietin alfa in chronic kidney disease
2008-004340-37Phase 3Terminated
- Sponsor
- Hexal AG
- Start
- Oct 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of epoetin alfa in anemia of renal disease and anaemia, sponsored by Hexal AG. Primary endpoints: Long-term safety of HX575 and Local tolerability at injection site. Started Oct 2008; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
anemia of renal diseaseanaemia
Beyond the preview
Go deeper on 2008-004340-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004340-37.